#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Diffuse large B-cell lymphoma refractory Mitochondrial myopathy Mastocytosis Paraneoplastic neurological syndrome Neoplasm malignant Thrombocytopenia Acute myeloid leukaemia refractory Microscopic polyangiitis Corneal neovascularisation Angiosarcoma recurrent Ureteric cancer Chemical burn Epileptic encephalopathy Lymphoma Deafness More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma – Trials in Disease Breast angiosarcoma metastatic – Treatment Hairy cell leukaemia recurrent – Treatment Prader-Willi syndrome – Basic Information Nephrotic syndrome – Diagnostics Stevens-Johnson syndrome – Trials in Disease Marginal zone lymphoma refractory – Treatment Systemic mastocytosis Piriformis syndrome – Diagnostics Atypical teratoid/rhabdoid tumour of CNS – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cln-081 FLUCLOXACILLIN SODIUM Fluorometholone RNK001 Methotrexate Disodium Budesonide Ab-729 Clavulanic Acid Ibuprofen Sodium Dihydrate 18F-Fludarabine Human Albumin Solution Pimavanserin Tartrate Nirmatrelvir Lsta1 Azd0305 Carmustine Hydralazine Hydrochloride Sertraline Hydrochloride SC0062 Baricitinib More therapies…

    Learn about Your Condition

    Head and neck cancer stage III Coronary artery dissection Metastatic gastric cancer Retinopathy proliferative Solitary fibrous tumour Juvenile psoriatic arthritis Prostate cancer metastatic Nephroblastoma Hernia repair Large cell lung cancer stage 0 Diabetic gastroparesis Osteosarcoma metastatic Cryoglobulinaemia Developmental hip dysplasia Escherichia infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Pathological Conditions, Signs and Symptoms

  • Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Glofitamab
    • Axicabtagene Ciloleucel
    • Lisocabtagene Maraleucel
    Germany

  • Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • AZD5335
    • Doxorubicin Hydrochloride, Liposomal
    Belgium Czechia Denmark France Germany Greece +4

  • A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Cardiac function disturbance postoperative
    • Acute kidney injury
    Investigated Drugs:
    • R2R01
    • Sodium Chloride
    Germany Italy

  • Study of the effect of hyperbaric oxygen therapy on the bacteria in chronic wounds

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Oxygen
    Austria

  • Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Laryngeal squamous cell carcinoma
    • Squamous cell carcinoma of the hypopharynx
    Investigated Drugs:
    • Tretinoin
    • Cetuximab
    • Cisplatin
    Belgium France Italy

  • Study of Piperacillin and Tazobactam Given Under the Skin Compared to a Vein in Patients with Infectious Diseases

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bacterial infection
    Investigated Drugs:
    • Piperacillin
    • Tazobactam
    Italy
1 2 3 … 21
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!